| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3127 | Lp-20 Hydrochloride | Potent ligand of the 5-HT7 receptor |
|
| DCC3128 | Lp-261 | Potent antimitotic and oral tubulin binding agent, significantly inhibiting growth of a human non-small-cell lung tumor |
|
| DCC3129 | Lp-922761 | Novel potent and selective peripheral AAK1 inhibitor |
|
| DCC3130 | Lp-925219 | Novel inhibitor of both renal SGLT1 and SGLT2 |
|
| DCC3131 | Lpa1-3 Agonist Cpx | Novel LPA 1-3 agonist, inducing a calcium response in hLPA 1-3 cells within a range of 0.4 to 1.5-log lower potency, as compared to LPA |
|
| DCC3132 | Lpa1-3 Agonist Cpy | Novel LPA 1-3 agonist, inducing a calcium response in hLPA 1-3 cells within a range of 0.4 to 1.5-log lower potency, as compared to LPA |
|
| DCC3133 | Lqfm030 | Novel p53 activator through the inhibition of MDM2 |
|
| DCC3134 | Lqmed 330 | Novel potent and specific inhibitor of O-linked β-N-acetylglucosamine transferase (OGT) |
|
| DCC3135 | Lrh-1 Agonist 10ca | Novel agonist of liver receptor homolog-1 (LRH-1), reducing the expression of lipogenic genes in mouse liver, and inflammation and disease severity in a mouse model of ulcerative colitis |
|
| DCC3136 | Lrh-1 Agonist-6n | Novel potent agonist of the liver receptor homolog-1 (LRH-1, NR5A2) |
|
| DCC3137 | Lrh-1 Inhibitor-3 | The first small molecule antagonist of LRH-1 activity. |
|
| DCC3138 | Lsd1 Inhibitor L8 | Novel selective and reversible LSD1 inhibitor (IC50 value of 60 nM), exhibiting the antiproliferative activity against HTB5, HTB3, HT1376, and HTB1 cells with IC50 values of 1.87, 0.18, 0.09, and 0.93 μM, respectively |
|
| DCC3139 | Lsd1-in-c26 | Novel selective inhibitor of histone lysine specific demethylase 1 (LSD1/KDM1A), displaying FAD-competitive binding to LSD1, concentration-dependently inducing accumulation of H3K4me1/me2 and H3K9me2, increasing expression levels of epithelial cell marker |
|
| DCC3140 | Lsf-oa | Novel prodrug of Lisofylline, maintaining a steady fasting blood glucose level with a significant increase in insulin level |
|
| DCC3141 | Lsf-pa | Novel prodrug of Lisofylline, maintaining a steady fasting blood glucose level with a significant increase in insulin level |
|
| DCC3142 | Lsm-4144 | First-in-class inhibitor of NF-κB signaling pathway by preventing the maturation of a rate-limiting multiprotein complex necessary for IKK activation |
|
| DCC3143 | Lsn3160440 | Novel positive allosteric modulator (PAM) of the GLP-1R, enhancing insulin secretion in a glucose-, ligand- and GLP-1R-dependent manner |
|
| DCC3144 | Lsn3172176 Precursor | Precursor for 11C-radiolabelling LSN3172176 PET scan |
|
| DCC3145 | Lsn335984 Trihydrochloride | Selective inhibitor of P-glycoproteins (P-gp) |
|
| DCC3146 | Lspn451 | Novel potent xanthine oxidase inhibitor |
|
| DCC3147 | Lt-106-175 | Novel potent inhibitor of FLT3 mutations, also inhibiting CDK2 and CDK6 |
|
| DCC3148 | Ethyl-3,4-dephostatin | Novel inhibitor of the interactions of CFTR-associated ligand (CAL) and PSD-95/Dlg1/ZO-1 (PDZ) domain |
|
| DCC3149 | L-threonyl-l-threonine | Peptide metabolite |
|
| DCC3150 | Lturm-36 | Novel PI 3-kinase delta inhibitor |
|
| DCC3151 | Lu Aa27122 | Brain penetrant high affinity α1A-adrenoceptor ligand |
|
| DCC3152 | Lu Aa41063 | Novel potent and selective hA2A receptor antagonist |
|
| DCC3153 | Lu Af58786 | Novel potent and selective inhibitor of LRRK2, inhibiting LRRK2 WT, the overactive variant G2019S, and the resistant mutant A2016T56 at 12 nM, 19 nM and 93 nM, respectively |
|
| DCC3154 | Lu Af58801 | Novel, potent, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors |
|
| DCC3155 | Lu-001i | Novel potent and selective LMP2 inhibitor, also inhibiting mouse 20S proteasomes |
|
| DCC3156 | Lu-002 | Novel β2-specific inhibitor, potently targeting both β2c and β2i, displaying moderate trypanocidal activity |
|
